Tags: Arthritis | lupus | drug | sifalimumab | astra

New Drugs Give Hope to Lupus Patients

Monday, 17 Nov 2014 07:55 AM

An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller.
 
Only one new drug -- GlaxoSmithKline's Benlysta -- has been introduced for lupus in half a century, underlining the difficulties of tackling the disease that causes the immune system to attack joints and organs.

AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.
 
 
 

In a Phase IIb study, details of which will be presented at the American College of Rheumatology (ACR) annual meeting, sifalimumab improved symptoms at all doses.

However, there was an increase in patients reporting Herpes zoster, particularly at the highest dose.

Sifalimumab is one of two drugs for lupus being developed by AstraZeneca's biotech unit MedImmune. The other is anifrolumab, which blocks interferon more comprehensively.

Early data, also being presented at the ACR meeting, suggests this second drug may be more effective.

Bing Yao, head of respiratory, inflammatory and autoimmune medicine at MedImmune, said the company would decide which of the two drugs to take into final-stage Phase III trials after getting Phase IIb results on anifrolumab next year.

In May, AstraZeneca predicted the lupus medicines could eventually generate annual sales of around $1 billion. It made the forecast as part of a long-term sales projection in its defense against an unsuccessful $118 billion takeover bid by Pfizer.

AstraZeneca will give a further update on its new drugs at an investor day on Nov. 18, just eight days before Pfizer is allowed to make a new bid under British takeover rules.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. Only one new drug --GlaxoSmithKline's Benlysta -- has been introduced...
lupus, drug, sifalimumab, astra
272
2014-55-17
Monday, 17 Nov 2014 07:55 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved